Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients

Journal of the American Society of Nephrology

Volumn 11, Issue 3, 2000, Pages 530-538

  Besarab, Anatole ^a,c   Amin, Neeta ^a   Ahsan, Muhammad ^a   Vogel, Susan E ^a   Zazuwa, Gary ^a   Frinak, Stanley ^a   Zazra, James J ^b   Anandan, J V ^a   Gupta, Ajay ^a  

^a HENRY FORD HOSPITAL   (United States)

^b Life Chem Labs   (United States)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; IRON DEFICIENCY; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSFERRIN BLOOD LEVEL; TREATMENT OUTCOME;

EID: 0034088831     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Eschbach JW, Kelly MR, Haley NR: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321: 158-163, 1989
2. Eschbach JW, Abdulhadi MH, Browne JK: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Intern Med 111: 992-1000, 1989
3. Besarab A, Flaharty KK, Erslev AJ: Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol 2: 1405-1416, 1992
4. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamaoto DM, Schwab SC, Goodkin DA: The effects of normal versus anemic hematocrit on hemodialysis patients with cardiac disease. N Engl J Med 339: 584-590, 1998
5. National Kidney Foundation-Dialysis Outcomes Quality Initiative: Clinical practice guidelines: Anemia of chronic renal failure. Am J Kidney Dis 30[Suppl 3]: S202-S212, 1997
6. Macdougall IC: Iron management in patients receiving erythropoietin therapy. Semin Dial 11: 10-13, 1998
7. Lindsay RM, Burton JA, King P: The measurement of dialyzer blood loss. Clin Nephrol 1: 24-28, 1973
8. Hörl WH: Consensus statement. How to diagnose and correct iron deficiency during rHuEpo therapy: A consensus report. Nephrol Dial Transplant 11: 246-250, 1996
9. Macdougall IC: Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens 3: 620-625, 1994
10. Macdougall IC, Cavill I, Hulme B: Detection of functional iron deficiency during erythropoietin treatment: A new approach. Br Med J 304: 225-226, 1992
11. Major A, Mathez-Loic F, Rohling R, Gautschi K, Brugnara C: The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol 98: 292-294, 1997
12. Eschbach JW, Haley NR, Egrie JC, Adamson JW: A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int 42: 407-416, 1992
13. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699, 1996
14. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41-46, 1995
15. Besarab A, Kaiser JW, Frinak S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 34: 21-27, 1999
16. Taylor JE, Peat N, Porter C, Morgan AG: Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11: 1079-1083, 1996
17. Sepandj F, Jindal K, West M, Hirsch D: Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11: 319-322, 1996
18. Besarab A, Frinak S, Yee J: An indistinct balance: The safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 10: 2029-2043, 1999
19. Auerbach M, Winchester J, Wahab A: A randomized trial of three iron dextran infusion methods for anemia in rHuEpotreated dialysis patients. Am J Kidney Dis 31: 81-86, 1998
20. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK: The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7: 2654-2657, 1996
21. Eschbach JW, Egrie JC, Downing MR, Brown JK, Adamson JW: Correction of anemia of end stage renal disease with rHu-EPO. N Engl J Med 316: 73-78, 1987
22. Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R: Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1: 652-655, 1982
23. Kernilde J-J, Folkert V, Mokrzycki M: Functional iron deficiency in hemodialysis patients with high ferritin levels [Abstract]. J Am Soc Nephrol 9: 253A, 1998
24. Fishbane S, Lynn RI: The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis 25: 426-432, 1995
25. Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK: Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 52: 217-222, 1997.
26. Mittman N, Sreedhara R, Mvshnick R: Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients. Am J Kidney Dis 30: 912-922, 1997
27. Cazzolla M, Huebers HA, Sayers MH, MacPhail PA, Eng M, Finch CA: Transferrin saturation, plasma iron turnover, and transferrin uptake in normal humans. Blood 66: 935-938, 1985
28. Huebers HA, Csiba E, Huebers E, Finch CA: Molecular advantage of diferric transferrin in delivering iron to reticulocytes: A comparative study. Proc Soc Exp Biol Med 179: 222-226, 1985
29. Cazzola M, Pootrakul P, Huebers HA, Eng M. Eschbach J, Finch CA: Erythroid marrow function in anemic patients. Blood 69: 296-301, 1987
30. Major A, Mathez-Loic F, Rohling R, Gautschi K, Brugnara C: The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol 98: 292-294, 1997
31. Breymann C, Bauer C, Major A, Zimmermann R, Gautschi K, Huch A, Huch R: Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers. Br J Haematol 92: 295-301, 1996
32. Braun J, Hammerschmidt M, Schreiber M: Is zinc protoporphyrin an indicator of iron-deficiency erythropoiesis on maintenance hemodialysis patients? Nephrol Dial Transplant 11: 492-497, 1996